Milestone Pharmaceuticals to Present Data on CARDAMYST™ (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session

About this update from Milestone Pharmaceuticals Inc.

[{"type":"image","alt":"Milestone Pharmaceuticals Inc.","displaySize":"","headline":null,"caption":"Milestone Pharmaceuticals Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":57,"url":"https://media.zenfs.com/en/globenewswire.com/a3e01b195c1ef10ed327d66d987e808c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/YgaHOGiuZH1uIXCqN0ZsAw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTgwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/a3e01b195c1ef10ed327d66d987e808c","width":300,"height":57}},"lazy":false},{"type":"text","content":"MONTREAL and CHARLOTTE, N.C., March 16, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that a moderated poster presentation titled “Minimal Blood Pressure Effects of Intranasal Etripamil in Trials for Paroxysmal Supraventricular Tachycardia (PSVT)” will be featured at the 2026 American College of Cardiology Annual Scientific Session (ACC.26), March 28-30th in New Orleans, La. An Expert Theater will also be conducted at ACC.26, providing a deeper look at this new treatment option for adults with symptomatic PSVT.","length":676,"tagName":"p"},{"type":"text","content":"“Although potential hypotension is a known class effect of calcium channel blockers, this analysis from Milestone’s etripamil Phase 3 program shows that etripamil had a minimal impact on blood pressure after test dosing and very low rates of hypotension,” said David Bharucha, M.D., PhD, Chief Medical Officer of Milestone Pharmaceuticals. “We believe these data support the potential for safe self-administration by patients of intranasal etripamil for PSVT outside the clinical setting.”","length":489,"tagName":"p"},{"type":"text","content":"Data Highlights","length":15,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Etripamil (CARDAMYST™), a novel calcium channel blocker (CCB) nasal spray, was FDA-approved as the first and only self-administered treatment for adults with symptomatic PSVT in December 2025 and is under investigation for atrial fibrillation with rapid ventricular rate. The Phase 3 trials that evaluated the product in PSVT included NODE-301 parts 1-3, NODE-302, and NODE-303.","length":378,"tagName":"p"}]},{"val":[{"type":"text","content...

More updates from Milestone Pharmaceuticals Inc.